Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BASIS: Bempedoic Acid vs Statins in Primary Prevention
NCT07239414Phase 3Not yet recruiting
- Start
- Nov 2025
- Primary completion
- Nov 2026
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of bempedoic acid in hypercholesterolemia (2 arms). Primary endpoints: Percentage change in LDL-C at 6 months and Composite adherence/tolerability endpoint at 6 months. Planned start Nov 2025; status: not yet recruiting.
02
Drugs
bempedoic acid
03
Conditions
hypercholesterolemia
Beyond the preview
Go deeper on NCT07239414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07239414.